Castrate-Resistant Prostate Cancer Epidemiology
DelveInsight's "Castrate-Resistant Prostate Cancer Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Castrate-Resistant Prostate Cancer (CRPC) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Geographies Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2021-2034
Castrate-Resistant Prostate Cancer (CRPC) Understanding
The DelveInsight Castrate-Resistant Prostate Cancer (CRPC) epidemiology report gives a thorough understanding of the Castrate-Resistant Prostate Cancer (CRPC) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Castrate-Resistant Prostate Cancer (CRPC) in the US, Europe, and Japan. The report covers the detailed information of the Castrate-Resistant Prostate Cancer (CRPC) epidemiology scenario in seven major countries (US, EU5, and Japan).
Unlock comprehensive insights! Click Here to Purchase the Full Market Report @ Castrate-Resistant Prostate Cancer Treatment Market Size
Castrate-Resistant Prostate Cancer (CRPC) Epidemiology Perspective by DelveInsight
The Castrate-Resistant Prostate Cancer (CRPC) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Castrate-Resistant Prostate Cancer (CRPC) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Castrate-Resistant Prostate Cancer (CRPC) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2021 to 2034. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
Castrate-Resistant Prostate Cancer (CRPC) Recent Developments
- In September 2024, Ipsen announced that the Phase III CONTACT-02 trial for Cabometyx® and atezolizumab in mCRPC showed a non-significant improvement in overall survival but met the progression-free survival (PFS) endpoint.
- In September 2024, Foundation Medicine received FDA approval for FoundationOne®CDx and Liquid CDx as companion diagnostics for Lynparza® in BRCA-mutated mCRPC.
- In July 2024, the ARANOTE trial showed that NUBEQA® plus ADT significantly improved radiological PFS in metastatic hormone-sensitive castrate-resistant prostate cancer (mHSPC).
- In July 2024, the FDA granted fast-track designation to SYNC-T SV-102 for metastatic castrate-resistant prostate cancer (mCRPC).
- In June 2024, Kangpu Biopharmaceuticals received FDA approval for a Phase II/III trial of KPG-121 with Abiraterone for mCRPC.
- In May 2024, Fusion Pharmaceuticals began the Phase 2 AlphaBreak trial of FPI-2265 in mCRPC patients.
- In April 2024, Astellas Pharma received European approval for XTANDI™ in high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer (nmHSPC).
- In April 2024, FibroGen announced positive Phase 1 trial data for FG-3246 in mCRPC.
Castrate-Resistant Prostate Cancer (CRPC) Detailed Epidemiology Segmentation
The Castrate-Resistant Prostate Cancer (CRPC) epidemiology covered in the report provides historical as well as forecasted Castrate-Resistant Prostate Cancer (CRPC) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2021 to 2034. The DelveInsight Castrate-Resistant Prostate Cancer (CRPC) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
Get More Insights of this Report @ Prostate Cancer Treatment Market Size
Scope of the Report
- The Castrate-Resistant Prostate Cancer (CRPC) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
- The Castrate-Resistant Prostate Cancer (CRPC) Epidemiology Report and Model provide an overview of the global trends of Castrate-Resistant Prostate Cancer (CRPC) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
- The report provides insight into the historical and forecasted patient pool of Castrate-Resistant Prostate Cancer (CRPC) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
- The report helps recognize the growth opportunities in the 7MM for the patient population
- The report assesses the disease risk and burden and highlights the unmet needs of Castrate-Resistant Prostate Cancer (CRPC)
- The report provides the segmentation of the Castrate-Resistant Prostate Cancer (CRPC) epidemiology
Take Your Research to the Next Level! Click Here to Get Access to the Full Pipeline Report @ Drugs for Castrate-Resistant Prostate Cancer
Report Highlights
- 10-year forecast of Castrate-Resistant Prostate Cancer (CRPC) epidemiology
- 7MM Coverage
- Prevalent and Diagnosed Cases of Castrate-Resistant Prostate Cancer (CRPC)
- Cases of Castrate-Resistant Prostate Cancer (CRPC) by Mutation Types
- Castrate-Resistant Prostate Cancer (CRPC) Cases associated with Clinical Manifestations
KOL views
We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
- What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Castrate-Resistant Prostate Cancer (CRPC)?
- What are the key findings pertaining to the Castrate-Resistant Prostate Cancer (CRPC) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2025-2034)?
- What would be the total number of patients of Castrate-Resistant Prostate Cancer (CRPC) across the 7MM during the forecast period (2025-2034)?
- Among the EU5 countries, which country will have the highest number of patients during the forecast period (2025-2034)?
- At what CAGR the patient population is expected to grow in 7MM during the forecast period (2025-2034)?
- What is the disease risk, burden and unmet needs of Castrate-Resistant Prostate Cancer (CRPC)?
- What are the currently available treatments of Castrate-Resistant Prostate Cancer (CRPC)?
Reasons to buy
The Castrate-Resistant Prostate Cancer (CRPC) Epidemiology report will allow the user to -
- Develop business strategies by understanding the trends shaping and driving the global Castrate-Resistant Prostate Cancer (CRPC) market
- Quantify patient populations in the global Castrate-Resistant Prostate Cancer (CRPC) market to improve product design, pricing, and launch plans
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Castrate-Resistant Prostate Cancer (CRPC) therapeutics in each of the markets covered
- Understand the magnitude of Castrate-Resistant Prostate Cancer (CRPC) population by its epidemiology
- The Castrate-Resistant Prostate Cancer (CRPC) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 10-year forecast period using reputable sources
Key Assessments
- Patient Segmentation
- Disease Risk & Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
Stay Updated with us for Recent Articles
